Thioguanine is a type of chemotherapy drug. It's used to treat certain types of cancer, like leukemia. It works by interfering with the cancer cells' ability to grow and divide. It's sometimes called Lanvis or Tabloid.
Every report comes from a Lived member, sent anonymously.
Have you tried Thioguanine for Acute Lymphoblastic Leukemia (ALL)?
Thioguanine is an oral chemotherapy tablet used to treat acute myeloid leukemia (AML), a fast-growing cancer of the blood-forming cells in the bone marrow. In the US it is sold as Tabloid; in Europe and some other countries it is sold as Lanvis, where it is also used for acute lymphoblastic leukemia. It is rarely given alone. It is one part of a combination chemotherapy plan, used during the intensive early phases of treatment that aim to clear leukemia from the marrow (induction) and then deepen that response (consolidation), because combinations bring on more remissions, and longer ones, than thioguanine by itself. Thioguanine does not work for chronic lymphocytic leukemia, Hodgkin lymphoma, multiple myeloma or solid tumors. Some gastroenterologists, mainly in Europe, also prescribe low doses off-label for inflammatory bowel disease (Crohn's disease and ulcerative colitis). Pooled studies of people taking it to keep Crohn's disease or ulcerative colitis under control suggest about two-thirds have a clinical response (their symptoms improved), but this use is not FDA-approved and needs the same blood and liver monitoring.
Thioguanine belongs to a group of medicines called purine analogs. Purines are building blocks of DNA and RNA, the genetic material every cell copies when it divides. Thioguanine closely resembles guanine, one of these building blocks, so cells take it up and convert it into look-alike building blocks (nucleotides). These look-alikes block the cell's own production of purines and get built into DNA and RNA in place of the real thing. Leukemia cells divide rapidly, so they are especially vulnerable to this disruption. Healthy cells that divide quickly, particularly in the bone marrow, are affected too, which is why blood counts drop during treatment. The active forms of the drug stay inside cells long after the tablet has left the bloodstream, so its effects on blood counts can keep developing for a while after a dose change or stop.
Thioguanine comes as a 40 mg scored tablet taken by mouth, usually once a day on the days it is scheduled. The dose is calculated from body size and set by the oncology team according to the specific chemotherapy protocol, and it is often adjusted from cycle to cycle based on blood counts. Absorption from the gut varies a great deal from person to person, which is another reason dosing is individual. Take it only as prescribed and only under the supervision of the treating team. Some people inherit low activity of TPMT (thiopurine methyltransferase) or NUDT15 (nudix hydrolase 15), two enzymes that help the body process this drug family. Without them, the drug builds up and can cause severe, rapid drops in blood counts at ordinary doses. People with two copies of a low-activity gene variant typically need about a tenth of the usual dose or less, and people with one copy sometimes need a reduction. A blood or genetic test can check for these variants, although a normal result does not rule out every risk, so blood counts are still monitored closely. Unlike the related drugs mercaptopurine and azathioprine, thioguanine does not need a dose reduction when it is taken with allopurinol (Zyloprim), a medicine often used during leukemia treatment to keep uric acid down. Chemotherapy tablets need careful handling; ask the pharmacy how to store and dispose of them safely at home.
The most important effect is lowered blood counts (bone marrow suppression). Low white blood cells make infections more likely and more serious, low platelets make bruising and bleeding easier, and low red blood cells cause tiredness, paleness and shortness of breath. During AML treatment, deep drops in counts are expected and often necessary for the chemotherapy to work, which is why the team checks blood counts frequently and has transfusions and infection treatment ready. Contact the care team right away for a fever, sore throat or other sign of infection, any unusual bleeding or bruising, or worsening tiredness or breathlessness, and follow the specific fever instructions the cancer team gives. Thioguanine can also damage the liver, usually by injuring the small blood vessels inside it. Signs include yellowing of the skin or eyes (jaundice), a tender or swollen abdomen and rapid weight gain from fluid buildup. If your skin or the whites of your eyes turn yellow, stop taking thioguanine and call the care team right away; liver injury can improve once the drug is stopped. Nausea, vomiting, loss of appetite and mouth sores are less common. As leukemia cells break down, they release uric acid, which can build up and strain the kidneys; plenty of fluids and medicines such as allopurinol help prevent this. European labeling also notes greater sensitivity to sunlight, so protective clothing and a strong sunscreen are sensible.
Thioguanine is not recommended for maintenance therapy or any similar long-term continuous treatment because of a high risk of liver damage. This was seen in a large share of children who took it daily for months to maintain remission of acute lymphoblastic leukemia, and it is more common in males. That warning comes from leukemia doses. The off-label use for inflammatory bowel disease is also long-term, but at much lower doses (often around 20 mg a day), and serious liver changes appear to become more likely as the dose rises. Liver injury is still possible at these doses, which is why gastroenterologists offer it only to selected people and check blood counts and liver tests regularly. Mesalamine, sulfasalazine and olsalazine, anti-inflammatory medicines used for ulcerative colitis, can block the TPMT enzyme and deepen the drop in blood counts, so they need caution alongside thioguanine. Other chemotherapy and radiation add to bone marrow suppression, which is one reason doses are coordinated within a protocol. Leukemia that has stopped responding to mercaptopurine usually will not respond to thioguanine either. Avoid live vaccines while immunity is weakened, and check with the team before any vaccination. Thioguanine can harm a developing baby. Pregnancy should be avoided during treatment, and European labeling advises both women and men to use contraception during treatment and for three months after stopping. Breastfeeding during treatment needs a decision with the team; European labeling advises against it. Because it acts on DNA, it carries a theoretical long-term cancer risk, which the oncology team weighs against the immediate need to treat leukemia.
Thioguanine is usually given in short courses within a larger chemotherapy schedule rather than continuously. During induction, blood counts typically fall low enough that many people need transfusions, infection precautions and sometimes a hospital stay before the marrow recovers. Because the drug's effects build inside cells, counts can keep falling for a time after a course ends, and the team may pause the drug at the first sign of an unusually steep drop. Expect frequent blood tests for complete blood counts, plus liver tests, typically weekly at the start of treatment and monthly afterward. Response depends heavily on the type of leukemia, the full regimen and the person's age and health; in AML, younger and otherwise healthier people generally do better with intensive treatment. Whether and when to repeat courses is decided by the oncology team based on how the leukemia responds and how well the blood counts and liver tolerate treatment.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Thioguanine, what you've noticed, or ask the community a question.